3 hours Trevi Therapeutics’ (TRVI) Buy Rating Reaffirmed at B. Riley MarketBeat
B. Riley reiterated a “buy” rating and set a $6.00 target price on shares of Trevi Therapeutics in a research note on Monday.
B. Riley reiterated a “buy” rating and set a $6.00 target price on shares of Trevi Therapeutics in a research note on Monday.